Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 1/2017

01-02-2017 | Original Paper

Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine

Authors: Mikkel Staberg, Signe Regner Michaelsen, Rikke Darling Rasmussen, Mette Villingshøj, Hans Skovgaard Poulsen, Petra Hamerlik

Published in: Cellular Oncology | Issue 1/2017

Login to get access

Abstract

Purpose

Glioblastoma (GBM) ranks among the deadliest solid cancers worldwide and its prognosis has remained dismal, despite the use of aggressive chemo-irradiation treatment regimens. Limited drug delivery into the brain parenchyma and frequent resistance to currently available therapies are problems that call for a prompt development of novel therapeutic strategies. While only displaying modest efficacies as mono-therapy in pre-clinical settings, histone deacetylase inhibitors (HDACi) have shown promising sensitizing effects to a number of cytotoxic agents. Here, we sought to investigate the sensitizing effect of the HDACi trichostatin A (TSA) to the alkylating agent lomustine (CCNU), which is used in the clinic for the treatment of GBM.

Methods

Twelve primary GBM cell cultures grown as neurospheres were used in this study, as well as one established GBM-derived cell line (U87 MG). Histone deacetylase (HDAC) expression levels were determined using quantitative real-time PCR and Western blotting. The efficacy of either CCNU alone or its combination with TSA was assessed using various assays, i.e., cell viability assays (MTT), cell cycle assays (flow cytometry, FACS), double-strand DNA break (DSB) quantification assays (microscopy/immunofluorescence) and expression profiling assays of proteins involved in apoptosis and cell stress (Western blotting and protein array).

Results

We found that the HDAC1, 3 and 6 expression levels were significantly increased in GBM samples compared to non-neoplastic brain control samples. Additionally, we found that pre-treatment of GBM cells with TSA resulted in an enhancement of their sensitivity to CCNU, possibly via the accumulation of DSBs, decreased cell proliferation and viability rates, and an increased apoptotic rate.

Conclusion

From our data we conclude that the combined administration of TSA and CCNU eradicates GBM cells with a higher efficacy than either drug alone, thereby opening a novel avenue for the treatment of GBM.
Appendix
Available only for authorised users
Literature
1.
R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, R.O. Mirimanoff, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 352, 987–996 (2005)CrossRefPubMed
2.
P.O. Sakariassen, H. Immervoll, M. Chekenya, Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia 9, 882–892 (2007)CrossRefPubMedPubMedCentral
3.
4.
M.B. Dhiab, S. Ziadi, S. Mestiri, R.B. Gacem, F. Ksiaa, M. Trimeche, DNA methylation patterns in EBV-positive and EBV-negative Hodgkin lymphomas. Cell. Oncol. 38, 453–462 (2015)CrossRef
5.
X. Xu, X. Chang, Z. Li, J. Wang, P. Deng, X. Zhu, J. Liu, C. Zhang, S. Chen, D. Dai, Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer. Cell. Oncol. 38, 183–194 (2015)CrossRef
6.
R.P. Nagarajan, J.F. Costello, Epigenetic mechanisms in glioblastoma multiforme. Semin. Cancer Biol. 19, 188–197 (2009)CrossRefPubMed
7.
C. Cortes, S.C. Kozma, A. Tauler, S. Ambrosio, MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells. Cell. Oncol. 38, 341–352 (2015)CrossRef
8.
9.
M.L. Di, G. Canettieri, P. Infante, A. Greco, A. Gulino, Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer. Biochim. Biophys. Acta 1815, 241–252 (2011)
10.
W. Weichert, HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280, 168–176 (2009)CrossRefPubMed
11.
12.
13.
K. Bajbouj, C. Mawrin, R. Hartig, J. Schulze-Luehrmann, A. Wilisch-Neumann, A. Roessner, R. Schneider-Stock, P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J. Neurooncol. 107, 503–516 (2012)CrossRefPubMed
14.
F.D. Sassi, L. Caesar, M. Jaeger, C. Nor, A.L. Abujamra, G. Schwartsmann, C.B. de Farias, A.L. Brunetto, P.L. Lopez, R. Roesler, Inhibitory activities of trichostatin A in U87 glioblastoma cells and tumorsphere-derived cells. J. Mol. Neurosci. 54, 27–40 (2014)CrossRef
15.
J.H. Kim, J.H. Shin, I.H. Kim, Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 59, 1174–1180 (2004)CrossRefPubMed
16.
J. Bartkova, P. Hamerlik, M.T. Stockhausen, J. Ehrmann, A. Hlobilkova, H. Laursen, O. Kalita, Z. Kolar, H.S. Poulsen, H. Broholm, J. Lukas, J. Bartek, Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 29, 5095–5102 (2010)CrossRefPubMed
17.
K. A. Harvey, Z. Xu, M. R. Saaddatzadeh, H. Wang, K. Pollok, A. A. Cohen-Gadol, R. A. Siddiqui, Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines. J. Neurosurg. 122, 547-556 (2015)
18.
S.H. Yang, Y.K. Hong, S.S. Jeun, I.S. Kim, J.T. Hong, J.H. Sung, B.C. Son, S.W. Lee, M.C. Kim, K.S. Lee, Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse. J. Neurooncol. 95, 23–28 (2009)CrossRefPubMed
19.
W. Taal, H.M. Oosterkamp, A.M. Walenkamp, H.J. Dubbink, L.V. Beerepoot, M.C. Hanse, J. Buter, A.H. Honkoop, D. Boerman, F.Y. de Vos, W.N. Dinjens, R.H. Enting, M.J. Taphoorn, F.W. van den Berkmortel, R.L. Jansen, D. Brandsma, J.E. Bromberg, I. van Heuvel, R.M. Vernhout, B. van der Holt, M.J. van den Bent, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 15, 943–953 (2014)CrossRefPubMed
20.
A.A. Brandes, M. Bartolotti, A. Tosoni, E. Franceschi, Nitrosoureas in the management of malignant gliomas. Curr. Neurol. Neurosci. Rep. 16, 13 (2016)CrossRefPubMed
21.
W. Wick, V.K. Puduvalli, M.C. Chamberlain, M.J. van den Bent, A.F. Carpentier, L.M. Cher, W. Mason, M. Weller, S. Hong, L. Musib, A.M. Liepa, D.E. Thornton, H.A. Fine, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28, 1168–1174 (2010)CrossRefPubMedPubMedCentral
22.
M.T. Stockhausen, H. Broholm, M. Villingshoj, M. Kirchhoff, T. Gerdes, K. Kristoffersen, M. Kosteljanetz, M. Spang-Thomsen, H.S. Poulsen, Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp. Cell Res. 317, 1513–1526 (2011)CrossRefPubMed
23.
R.D. Rasmussen, M.K. Gajjar, K.E. Jensen, P. Hamerlik, Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. Mol. Oncol. 10, 751–763 (2016)CrossRefPubMed
24.
P. Hamerlik, J.D. Lathia, R. Rasmussen, Q. Wu, J. Bartkova, M. Lee, P. Moudry, J. Bartek Jr., W. Fischer, J. Lukas, J.N. Rich, J. Bartek, Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J. Exp. Med. 209, 507–520 (2012)CrossRefPubMedPubMedCentral
25.
M. Wetzel, D.R. Premkumar, B. Arnold, I.F. Pollack, Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. J. Neurosurg. 103, 549–556 (2005)PubMed
26.
M. Koprinarova, P. Botev, G. Russev, Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination. DNA Repair 10, 970–977 (2011)CrossRefPubMed
27.
A.S. Balajee, C.R. Geard, Replication protein A and gamma-H2AX foci assembly is triggered by cellular response to DNA double-strand breaks. Exp. Cell Res. 300, 320–334 (2004)CrossRefPubMed
28.
C. Adamson, O.O. Kanu, A.I. Mehta, C. Di, N. Lin, A.K. Mattox, D.D. Bigner, Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin. Investig. Drugs 18, 1061–1083 (2009)CrossRefPubMed
29.
W. Weichert, A. Roske, V. Gekeler, T. Beckers, C. Stephan, K. Jung, F.R. Fritzsche, S. Niesporek, C. Denkert, M. Dietel, G. Kristiansen, Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 98, 604–610 (2008)CrossRefPubMedPubMedCentral
30.
W. Weichert, A. Roske, S. Niesporek, A. Noske, A.C. Buckendahl, M. Dietel, V. Gekeler, M. Boehm, T. Beckers, C. Denkert, Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 14, 1669–1677 (2008)CrossRefPubMed
31.
C.A. Krusche, P. Wulfing, C. Kersting, A. Vloet, W. Bocker, L. Kiesel, H.M. Beier, J. Alfer, Histone deacetylase-1 and −3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat. 90, 15–23 (2005)CrossRefPubMed
32.
Y. Minamiya, T. Ono, H. Saito, N. Takahashi, M. Ito, S. Motoyama, J. Ogawa, Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumour Biol. 31, 533–539 (2010)CrossRefPubMed
33.
T. Rikimaru, A. Taketomi, Y. Yamashita, K. Shirabe, T. Hamatsu, M. Shimada, Y. Maehara, Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72, 69–74 (2007)CrossRefPubMed
34.
W. Weichert, A. Roske, V. Gekeler, T. Beckers, M.P. Ebert, M. Pross, M. Dietel, C. Denkert, C. Rocken, Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 9, 139–148 (2008)CrossRefPubMed
35.
M. Venere, P. Hamerlik, Q. Wu, R.D. Rasmussen, L.A. Song, A. Vasanji, N. Tenley, W.A. Flavahan, A.B. Hjelmeland, J. Bartek, J.N. Rich, Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 21, 258–269 (2014)CrossRefPubMed
36.
T.C. Karagiannis, K.N. Harikrishnan, A. El-Osta, The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X. Cancer Biol. Ther. 4, 787–793 (2005)CrossRefPubMed
37.
B. Sarcar, S. Kahali, P. Chinnaiyan, Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. J. Neurooncol. 99, 201–207 (2010)CrossRefPubMed
38.
C.H. Ryu, W.S. Yoon, K.Y. Park, S.M. Kim, J.Y. Lim, J.S. Woo, C.H. Jeong, Y. Hou, S.S. Jeun, Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J. Biomed. Biotechnol. 2012(987495) (2012)
39.
A. Ferraro, Altered primary chromatin structures and their implications in cancer development. Cell. Oncol. 39, 195–210 (2016)CrossRef
40.
A.J. de Ruijter, A.H. van Gennip, H.N. Caron, S. Kemp, A.B. van Kuilenburg, Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737–749 (2003)CrossRefPubMedPubMedCentral
41.
A.K. Lucio-Eterovic, M.A. Cortez, E.T. Valera, F.J. Motta, R.G. Queiroz, H.R. Machado, C.G. Carlotti Jr., L. Neder, C.A. Scrideli, L.G. Tone, Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 8, 243 (2008)CrossRefPubMedPubMedCentral
42.
V. Medina, B. Edmonds, G.P. Young, R. James, S. Appleton, P.D. Zalewski, Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 57, 3697–3707 (1997)PubMed
43.
H. Sawa, H. Murakami, Y. Ohshima, T. Sugino, T. Nakajyo, T. Kisanuki, Y. Tamura, A. Satone, W. Ide, I. Hashimoto, H. Kamada, Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 18, 109–114 (2001)CrossRefPubMed
44.
G. Aquilina, M. Crescenzi, M. Bignami, Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage. Carcinogenesis 20, 2317–2326 (1999)CrossRefPubMed
45.
Z. Shinwari, H. Al-Hindi, E. Al-Shail, Y. Khafaga, A. Al-Kofide, N. El-Kum, A. Aboussekhra, Response of medulloblastoma cells to vincristine and lomustine: role of TRKC, CTNNB1 and STK15. Anticancer Res. 31, 1721–1733 (2011)PubMed
46.
M. Cornago, C. Garcia-Alberich, N. Blasco-Angulo, N. Vall-Llaura, M. Nager, J. Herreros, J.X. Comella, D. Sanchis, M. Llovera, Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis. 5, e1435 (2014)CrossRefPubMedPubMedCentral
47.
K.M. Miller, J.V. Tjeertes, J. Coates, G. Legube, S.E. Polo, S. Britton, S.P. Jackson, Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat. Struct. Mol. Biol. 17, 1144–1151 (2010)CrossRefPubMedPubMedCentral
48.
S. Bhaskara, B.J. Chyla, J.M. Amann, S.K. Knutson, D. Cortez, Z.W. Sun, S.W. Hiebert, Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol. Cell 30, 61–72 (2008)CrossRefPubMedPubMedCentral
49.
E.P. Rogakou, W. Nieves-Neira, C. Boon, Y. Pommier, W.M. Bonner, Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J. Biol. Chem. 275, 9390–9395 (2000)CrossRefPubMed
50.
A. Duensing, X. Teng, Y. Liu, M. Tseng, N. Spardy, S. Duensing, A role of the mitotic spindle checkpoint in the cellular response to DNA replication stress. J. Cell. Biochem. 99, 759–769 (2006)CrossRefPubMedPubMedCentral
51.
E. Diss, N. Nalabothula, D. Nguyen, E. Chang, Y. Kwok, F. Carrier, Vorinostat promotes hyper-radiosensitivity in wild type p53 human glioblastoma cells. J. Clin. Oncol. Res. 2, 1–9 (2014)
52.
A. Min, S.A. Im, D.K. Kim, S.H. Song, H.J. Kim, K.H. Lee, T.Y. Kim, S.W. Han, D.Y. Oh, T.Y. Kim, M.J. O’Connor, Y.J. Bang, Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res. 17, 33 (2015)CrossRefPubMedPubMedCentral
53.
O.S. Chao, O.B. Goodman Jr., Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP. Mol. Cancer Res. 12, 1755–1766 (2014)CrossRefPubMed
54.
P.A. Konstantinopoulos, A.J. Wilson, J. Saskowski, E. Wass, D. Khabele, Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol. Oncol. 133, 599–606 (2014)CrossRefPubMedPubMedCentral
55.
A. Kretsovali, C. Hadjimichael, N. Charmpilas, Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int. 2012, 1–10 184154 (2012)
Metadata
Title
Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine
Authors
Mikkel Staberg
Signe Regner Michaelsen
Rikke Darling Rasmussen
Mette Villingshøj
Hans Skovgaard Poulsen
Petra Hamerlik
Publication date
01-02-2017
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 1/2017
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0301-9

Other articles of this Issue 1/2017

Cellular Oncology 1/2017 Go to the issue

Original Paper

Collective cell migration of thyroid carcinoma cells: a beneficial ability to override unfavourable substrates

Review

Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer

Report

Erufosine increases RhoB expression in oral squamous carcinoma cells independent of its tumor suppressive mode of action - a short report

Original Paper

Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia

Original Paper

miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma

Short Communication

MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits